{"DataElement":{"publicId":"13381490","version":"1","preferredName":"Disease Tumor Response System Type","preferredDefinition":"The type of standard from which a judgment concerning tumor response to therapy can be established.","longName":"13362468v1.00:13378548v1.00","context":"Pediatric Cancer","contextVersion":"1","DataElementConcept":{"publicId":"13362468","version":"1","preferredName":"Disease Tumor Response System","preferredDefinition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.:A standard from which a judgment concerning tumor response to therapy can be established.","longName":"2607696v1.00:13362467v1.00","context":"Pediatric Cancer","contextVersion":"1","ObjectClass":{"publicId":"2607696","version":"1","preferredName":"Response","preferredDefinition":"In medicine, an improvement related to treatment.","longName":"C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2AF31F79-4CA1-08D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-03-05","endDate":null,"createdBy":"UMLLOADER_CTOM","dateCreated":"2007-03-05","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"13362467","version":"1","preferredName":"Tumor Response System","preferredDefinition":"A standard from which a judgment concerning tumor response to therapy can be established.","longName":"C125932","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Response System","conceptCode":"C125932","definition":"A standard from which a judgment concerning tumor response to therapy can be established.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F97C4661-CF58-6457-E053-731AD00ACD27","latestVersionIndicator":"Yes","beginDate":"2023-04-16","endDate":null,"createdBy":"JKNABLE","dateCreated":"2023-04-16","modifiedBy":"JKNABLE","dateModified":"2023-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"PCDC:Pediatric Cancer Data Commons","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"F97C4661-CF59-6457-E053-731AD00ACD27","latestVersionIndicator":"Yes","beginDate":"2023-04-16","endDate":null,"createdBy":"JKNABLE","dateCreated":"2023-04-16","modifiedBy":"JKNABLE","dateModified":"2023-04-16","changeDescription":null,"administrativeNotes":"4/16/23 Created for the PCDC-C3DC Aggregated Dictionary data elements. jk","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"13378548","version":"1","preferredName":"Tumor Response System Type","preferredDefinition":"A standard from which a judgment concerning tumor response to therapy can be established._Something distinguishable as an identifiable class based on common qualities.","longName":"13378548v1.00","context":"Pediatric Cancer","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Choi","valueDescription":null,"ValueMeaning":{"publicId":"6658567","version":"1","preferredName":"Choi Response Criteria in the Evaluation of Gastrointestinal Stromal Tumors","longName":"6658567","preferredDefinition":"A composite set of criteria developed by Choi et al. using imaging techniques in the evaluation of gastrointestinal stromal tumors response to imatinib mesylate treatment. These criteria integrate changes in tumor size and tumor density.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choi Response Criteria in the Evaluation of Gastrointestinal Stromal Tumors","conceptCode":"C122394","definition":"A composite set of criteria developed by Choi et al. using imaging techniques in the evaluation of gastrointestinal stromal tumors response to imatinib mesylate treatment. These criteria integrate changes in tumor size and tumor density.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"827F88F0-383F-6926-E053-F662850AFE98","latestVersionIndicator":"Yes","beginDate":"2019-02-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-02-22","modifiedBy":"ONEDATA","dateModified":"2019-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9B39F8B-BB1F-0DEC-E053-731AD00A216C","beginDate":"2023-04-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-19","modifiedBy":"SOKKERL","dateModified":"2023-04-19","deletedIndicator":"No"},{"value":"mRECIST","valueDescription":null,"ValueMeaning":{"publicId":"6658631","version":"1","preferredName":"Modified RECIST Byrne Mesothelioma 2004 Oncology Response Criteria","longName":"6658631","preferredDefinition":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. (Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004 Feb;15(2):257-60.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Modified RECIST Byrne Mesothelioma 2004 Oncology Response Criteria","conceptCode":"C126031","definition":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. (Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004 Feb;15(2):257-60.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"827FB37F-94E0-1F65-E053-F662850A18DE","latestVersionIndicator":"Yes","beginDate":"2019-02-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-02-22","modifiedBy":"ONEDATA","dateModified":"2019-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9B39F8B-BB20-0DEC-E053-731AD00A216C","beginDate":"2023-04-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-19","modifiedBy":"SOKKERL","dateModified":"2023-04-19","deletedIndicator":"No"},{"value":"PERCIST","valueDescription":null,"ValueMeaning":{"publicId":"6658649","version":"1","preferredName":"PET Response Criteria in Solid Tumors","longName":"6658649","preferredDefinition":"From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. (Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009 May;50 Suppl 1:122S-50S.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PET Response Criteria in Solid Tumors","conceptCode":"C126039","definition":"A set of rules that define when tumors in cancer patients respond, stabilize, or progress during treatment with respect to positron emission tomography.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"827FB37F-9636-1F65-E053-F662850A18DE","latestVersionIndicator":"Yes","beginDate":"2019-02-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-02-22","modifiedBy":"ONEDATA","dateModified":"2019-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9B39F8B-BB21-0DEC-E053-731AD00A216C","beginDate":"2023-04-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-19","modifiedBy":"SOKKERL","dateModified":"2023-04-19","deletedIndicator":"No"},{"value":"RECIST","valueDescription":null,"ValueMeaning":{"publicId":"2627734","version":"1","preferredName":"Response Evaluation Criteria in Solid Tumors","longName":"2627734","preferredDefinition":"Standard parameters to be used when documenting response of solid tumors to treatment; a set of published rules that define when cancer patients improve (\"respond\"), stay the same (\"stable\"), or worsen (\"progression\") during treatments. (from www.recist.com)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Response Evaluation Criteria in Solid Tumors","conceptCode":"C49164","definition":"Standard parameters to be used when documenting response of solid tumors to treatment; a set of published rules that define when cancer patients improve (\"respond\"), stay the same (\"stable\"), or worsen (\"progression\") during treatments. (from www.recist.com)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E04FCDB-148F-1B41-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9B39F8B-BB22-0DEC-E053-731AD00A216C","beginDate":"2023-04-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-19","modifiedBy":"SOKKERL","dateModified":"2023-04-19","deletedIndicator":"No"},{"value":"WHO","valueDescription":null,"ValueMeaning":{"publicId":"5505430","version":"1","preferredName":"World Health Organization","longName":"5505430","preferredDefinition":"A United Nations agency established to coordinate international health activities and to help governments improve health services.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"World Health Organization","conceptCode":"C75419","definition":"A United Nations agency established to coordinate international health activities and to help governments improve health services.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E226479-D69C-4C44-E053-F662850ACF90","latestVersionIndicator":"Yes","beginDate":"2016-10-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9B39F8B-BB23-0DEC-E053-731AD00A216C","beginDate":"2023-04-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-19","modifiedBy":"SOKKERL","dateModified":"2023-04-19","deletedIndicator":"No"},{"value":"Unknown","valueDescription":null,"ValueMeaning":{"publicId":"5682953","version":"1","preferredName":"Unknown","longName":"5682953","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B4645-0FC6-0802-E053-F662850AB305","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9B39F8B-BB24-0DEC-E053-731AD00A216C","beginDate":"2023-04-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-19","modifiedBy":"SOKKERL","dateModified":"2023-04-19","deletedIndicator":"No"},{"value":"Not Reported","valueDescription":null,"ValueMeaning":{"publicId":"5612322","version":"1","preferredName":"Not Reported","longName":"5612322v1.00","preferredDefinition":"Not provided or available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Reported","conceptCode":"C43234","definition":"Not provided or available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45340835-3B00-7C78-E053-F662850A44F9","latestVersionIndicator":"Yes","beginDate":"2017-01-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-01-03","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"10/10/23 changed Long Name from \"Not Stated\" to match NCIt Preferred name and current caDSR concept Long Name of \"Not Reported\" per Brenda.Janice . LS","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9B39F8B-BB25-0DEC-E053-731AD00A216C","beginDate":"2023-04-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-19","modifiedBy":"SOKKERL","dateModified":"2023-04-19","deletedIndicator":"No"},{"value":"iRANO","valueDescription":null,"ValueMeaning":{"publicId":"5914107","version":"1","preferredName":"Immunotherapy Response Assessment in Neuro-Oncology Criteria","longName":"5914107","preferredDefinition":"Response assessment criteria for the evaluation of patients undergoing immunotherapy for the treatment of malignant glioma. These recommendations integrate guidance for the determination and confirmation of tumor progression based on the response assessment in neuro-oncology (RANO) working group and the immune-related response criteria (irRC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunotherapy Response Assessment in Neuro-Oncology Criteria","conceptCode":"C131131","definition":"Response assessment criteria for the evaluation of patients undergoing immunotherapy for the treatment of malignant glioma. These recommendations integrate guidance for the determination and confirmation of tumor progression based on the response assessment in neuro-oncology (RANO) working group and the immune-related response criteria (irRC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54A09267-EE80-6E45-E053-F662850A7CBF","latestVersionIndicator":"Yes","beginDate":"2017-07-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-07-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9B39F8B-BB26-0DEC-E053-731AD00A216C","beginDate":"2023-04-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-19","modifiedBy":"SOKKERL","dateModified":"2023-04-19","deletedIndicator":"No"},{"value":"RANO","valueDescription":null,"ValueMeaning":{"publicId":"6658658","version":"1","preferredName":"Response Assessment in Neuro-Oncology Criteria","longName":"6658658","preferredDefinition":"An update to the MacDonald criteria for assessing disease progression and treatment response in glioblastoma multiforme (GBM).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Response Assessment in Neuro-Oncology Criteria","conceptCode":"C114879","definition":"An update to the MacDonald criteria for assessing disease progression and treatment response in glioblastoma multiforme (GBM).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"827FCCFE-5DA9-1CE3-E053-F662850A1249","latestVersionIndicator":"Yes","beginDate":"2019-02-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-02-22","modifiedBy":"ONEDATA","dateModified":"2019-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9B39F8B-BB27-0DEC-E053-731AD00A216C","beginDate":"2023-04-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-19","modifiedBy":"SOKKERL","dateModified":"2023-04-19","deletedIndicator":"No"},{"value":"Modified MacDonald","valueDescription":null,"ValueMeaning":{"publicId":"13415065","version":"1","preferredName":"Modified Macdonald Tumor Response Criteria","longName":"13415065v1.00","preferredDefinition":"A response criteria for high-grade gliomas that utilizes measurements of contrast enhancing tumor size combined with corticosteroid dosing levels and other clinical metrics to determine treatment response and tumor progression, with response stratified into four categories: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Modified Macdonald Tumor Response Criteria","conceptCode":"C198862","definition":"A response criteria for high-grade gliomas that utilizes measurements of contrast enhancing tumor size combined with corticosteroid dosing levels and other clinical metrics to determine treatment response and tumor progression, with response stratified into four categories: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9DCA228-3453-347B-E053-731AD00AE97E","latestVersionIndicator":"Yes","beginDate":"2023-04-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-21","modifiedBy":"SOKKERL","dateModified":"2023-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9DCA228-3457-347B-E053-731AD00AE97E","beginDate":"2023-04-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-21","modifiedBy":"SOKKERL","dateModified":"2023-04-21","deletedIndicator":"No"},{"value":"RAPNO","valueDescription":null,"ValueMeaning":{"publicId":"13415066","version":"1","preferredName":"RAPNO Tumor Response Criteria","longName":"13415066v1.00","preferredDefinition":"A response criteria for pediatric high- and low-grade gliomas, and diffuse intrinsic pontine gliomas (DIPG) that uses two-dimensional measurements of tumors, combined with clinical and functional outcomes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"RAPNO Tumor Response Criteria","conceptCode":"C198863","definition":"A response criteria for pediatric high- and low-grade gliomas, and diffuse intrinsic pontine gliomas (DIPG) that uses two-dimensional measurements of tumors, combined with clinical and functional outcomes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9DCA228-3454-347B-E053-731AD00AE97E","latestVersionIndicator":"Yes","beginDate":"2023-04-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-21","modifiedBy":"SOKKERL","dateModified":"2023-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9DCA228-3458-347B-E053-731AD00AE97E","beginDate":"2023-04-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-21","modifiedBy":"SOKKERL","dateModified":"2023-04-21","deletedIndicator":"No"},{"value":"INRC, Park 2017","valueDescription":null,"ValueMeaning":{"publicId":"13415067","version":"1","preferredName":"International Neuroblastoma Response Criteria, Park 2017","longName":"13415067v1.00","preferredDefinition":"A revised version of the International Neuroblastoma Response Criteria (INRC) that incorporates modern imaging techniques and new methods for quantifying bone marrow disease. Overall response in the revised INRC integrates tumor response in the primary tumor, soft tissue and bone metastases, and bone marrow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"International Neuroblastoma Response Criteria, Park 2017","conceptCode":"C198864","definition":"A revised version of the International Neuroblastoma Response Criteria (INRC) that incorporates modern imaging techniques and new methods for quantifying bone marrow disease. Overall response in the revised INRC integrates tumor response in the primary tumor, soft tissue and bone metastases, and bone marrow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9DCA228-3455-347B-E053-731AD00AE97E","latestVersionIndicator":"Yes","beginDate":"2023-04-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-21","modifiedBy":"SOKKERL","dateModified":"2023-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9DCA228-3459-347B-E053-731AD00AE97E","beginDate":"2023-04-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-21","modifiedBy":"SOKKERL","dateModified":"2023-04-21","deletedIndicator":"No"},{"value":"INRC, Brodeur 1993","valueDescription":null,"ValueMeaning":{"publicId":"13415068","version":"1","preferredName":"International Neuroblastoma Response Criteria, Brodeur 1993","longName":"13415068v1.00","preferredDefinition":"A revision of the International Neuroblastoma Staging System (INSS) and International Neuroblastoma Response Criteria (INRC). The revisions included redefinition of the midline, restrictions on age and bone marrow involvement for stage 4S, and the recommendation that meta-iodobenzylguanidine (MIBG) scanning be implemented for evaluating the extent of disease. The biologic features that were deemed important to evaluate included serum ferritin, neuron-specific enolase (NSE), and lactic dehydrogenase (LDH); tumor histology; tumor-cell DNA content; assessment of N-Myc copy number; assessment of chromosome 1p deletion by cytogenetic or molecular methods; and high affinity nerve growth factor receptor (Trk-A) expression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"International Neuroblastoma Response Criteria, Brodeur 1993","conceptCode":"C198865","definition":"A revision of the International Neuroblastoma Staging System (INSS) and International Neuroblastoma Response Criteria (INRC). The revisions included redefinition of the midline, restrictions on age and bone marrow involvement for stage 4S, and the recommendation that meta-iodobenzylguanidine (MIBG) scanning be implemented for evaluating the extent of disease. The biologic features that were deemed important to evaluate included serum ferritin, neuron-specific enolase (NSE), and lactic dehydrogenase (LDH); tumor histology; tumor-cell DNA content; assessment of N-Myc copy number; assessment of chromosome 1p deletion by cytogenetic or molecular methods; and high affinity nerve growth factor receptor (Trk-A) expression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9DCA228-3456-347B-E053-731AD00AE97E","latestVersionIndicator":"Yes","beginDate":"2023-04-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-21","modifiedBy":"SOKKERL","dateModified":"2023-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9DCA228-345A-347B-E053-731AD00AE97E","beginDate":"2023-04-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-21","modifiedBy":"SOKKERL","dateModified":"2023-04-21","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435018","version":"1","preferredName":"Clinical or Research Activity","preferredDefinition":"Any specific activity undertaken during the course of a clinical study or research protocol.","longName":"C16203","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741AE5B-831E-25C7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"13378547","version":"1","preferredName":"Tumor Response System Type","preferredDefinition":"A standard from which a judgment concerning tumor response to therapy can be established._Something distinguishable as an identifiable class based on common qualities.","longName":"13378547v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Response System","conceptCode":"C125932","definition":"A standard from which a judgment concerning tumor response to therapy can be established.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9B1FC30-B02F-3841-E053-731AD00A92EC","latestVersionIndicator":"Yes","beginDate":"2023-04-19","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-04-19","modifiedBy":"COLBERTM","dateModified":"2023-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"PCDC:Pediatric Cancer Data Commons","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"F9B1FC30-B030-3841-E053-731AD00A92EC","latestVersionIndicator":"Yes","beginDate":"2023-04-19","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-04-19","modifiedBy":"SOKKERL","dateModified":"2023-04-21","changeDescription":null,"administrativeNotes":"4/19/23 Created per PCDC metadata template. mr","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"12173174","version":"1","longName":"PCDC Aggregated Dictionary","context":"Pediatric Cancer","ClassificationSchemeItems":[{"publicId":"12173180","version":"1","longName":"Response","context":"Pediatric Cancer"},{"publicId":"12173216","version":"1","longName":"Subject Response","context":"Pediatric Cancer"}]},{"publicId":"13954630","version":"1","longName":"All Pediatric Core CDEs","context":"Pediatric Cancer","ClassificationSchemeItems":[{"publicId":"14599256","version":"1","longName":"Clinical Observation","context":"Pediatric Cancer"}]}],"AlternateNames":[{"name":"RESPONSE_SYSTEM","type":"PCDC Alt Name","context":"Pediatric Cancer"},{"name":"Response System","type":"Ped Cancer Alt Name","context":"Pediatric Cancer"}],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Response System","url":null,"context":"Pediatric Cancer"}],"origin":"PCDC:Pediatric Cancer Data Commons","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"F9B58DE0-0BD3-644F-E053-731AD00A71C7","latestVersionIndicator":"Yes","beginDate":"2023-04-19","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-04-19","modifiedBy":"FINCHAMB","dateModified":"2024-02-22","changeDescription":null,"administrativeNotes":"2/22/24 Added Ped Core Alts, CSI per PCDC/MW recommendations. BF;4/19/23 Curated for PCDC. BF","unresolvedIssues":null,"deletedIndicator":"No"}}